Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus XYZAL ALLERGY 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus XYZAL ALLERGY 24HR.
ACTIDIL vs XYZAL ALLERGY 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses such as itching, sneezing, and rhinorrhea.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
5 mg (1 tablet) orally once daily, preferably in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life is approximately 8-9 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged to up to 21 hours.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal excretion; approximately 85% of the dose is excreted unchanged in urine, with the remainder as metabolites (mainly the conjugate) in feces via biliary elimination (~10-13%).
Category C
Category C
Antihistamine
Antihistamine